Taysha Gene Therapies Inc expected to post a loss of 82 cents a share - Earnings Preview

Taysha Gene Therapies

04/11/2022 19:34

* Taysha Gene Therapies Inc  TSHA.OQ   TSHA.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 8. 
    * 
    * ​Refinitiv's mean analyst estimate for Taysha Gene
Therapies Inc
is for a loss of 82 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Taysha Gene
Therapies Inc is $22​, above​ its last closing price of $1.95.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -1.04       -1.00      -0.84     Beat    16.4
 Mar. 31 2022  -1.09       -1.07      -1.31     Missed  -22.8
 Dec. 31 2021  -1.25       -1.25      -1.32     Missed  -5.2​
 Sep. 30 2021  -1.11       -1.08      -1.35     Missed  -25.2
 ​​Jun.        -0.85       -0.84      -1.09     Missed  -29.8
 30 2021                                                
 Mar. 31 2021  -0.67       -0.56      -0.87     Missed  -54.6​
 Dec. 31 2020  -0.42       -0.37      -1.04     Missed  -177.3
 Sep. 30 2020  -0.17       -0.17      -1.28     Missed  -631.4
 This summary was machine generated November 4 at 19:34 GMT.  All
figures in US dollars  unless otherwise stated